Evaluation of the Efficacy and Safety of a 4-month Daily Regimen (2HZPM/2HPM) for Treatment of Pulmonary TB

The development of efficacious, safe, and shorter treatment regimens could significantly improve TB management and treatment success rates. This prospective, 3-year, single arm study is to evaluate the efficacy and safety of a short-course, 4-month regimen including isoniazid(H), pyrazinamide(P), rifapentine (P), and moxifloxacin(M) (2HZPM/2HPM) for the treatment of drug-susceptible, pulmonary tuberculosis, and compared with a historical control group receiving the standard six-month regimen.

NCT Number	NCT04856644
Lead Sponsor	Kaohsiung Veterans General Hospital. Collaborators: National Taiwan University, Taipei Veterans General Hospital, Taiwan, Chang Gung Memorial Hospital, Centers for Disease Control, Taiwan
Conditions	Tuberculosis, Pulmonary
Enrollment	333 participants
Start Date	2020-01-01
Primary Completion	2023-12-31 (estimated)
Study Completion	2024-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-07-12